Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct 19;2(1):e000327.
doi: 10.1136/openhrt-2015-000327. eCollection 2015.

Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes

James J DiNicolantonio  1 , Jaikrit Bhutani  2 , James H O'Keefe  1
Affiliations
Review

Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes

James J DiNicolantonio et al. Open Heart. .

Abstract

α-Glucosidase inhibitors (AGIs) are a class of oral glucose-lowering drugs used exclusively for treatment or prevention of type 2 diabetes mellitus. AGIs act by altering the intestinal absorption of carbohydrates through inhibition of their conversion into simple sugars (monosaccharides) and thus decrease the bioavailability of carbohydrates in the body, significantly lowering blood glucose levels. The three AGIs used in clinical practice are acarbose, voglibose and miglitol. This review will focus on the cardiovascular properties of acarbose. The current available data suggest that AGIs (particularly acarbose) may be safe and effective for the treatment of prediabetes and diabetes.

Keywords: acarbose; alpha-glucosidase; type 2 diabetes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci 2012;8:899–906. 10.5114/aoms.2012.31621 - DOI - PMC - PubMed
    1. Puls W. Pharmacology of glucosidase inhibitors. In: Kuhlmann J, Puls W, eds. Oral antidiabetics. Springer, 1996:497–534.
    1. Krause H, Ahr H. Pharmacokinetics and metabolism of glucosidase inhibitors. In: Kuhlmann J, Puls W, eds. Oral antidiabetics. Springer, 1996:541–55.
    1. Gross LS, Li L, Ford ES et al. . Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr 2004;79:774–9. - PubMed
    1. Dinicolantonio JJ. The cardiometabolic consequences of replacing saturated fats with carbohydrates or Ω-6 polyunsaturated fats: do the dietary guidelines have it wrong? Open Heart 2014;1:e000032 10.1136/openhrt-2013-000032 - DOI - PMC - PubMed

LinkOut - more resources

-